Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C62H86N12O16 |
Molecular Weight | 1255.417 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C3=C4N=C5C(OC4=C(C)C=C3)=C(C)C(=O)C(N)=C5C(=O)N[C@H]6[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@H](NC6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C
InChI
InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N
InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
Molecular Formula | C62H86N12O16 |
Molecular Weight | 1255.417 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954
Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
156.25 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
25.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931 |
1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
142.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.67 μg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931 |
1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931 |
1.1 mg/m² unknown, intravenous dose: 1.1 mg/m² route of administration: Intravenous experiment type: UNKNOWN co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Other AEs: Pancytopenia, Mucositis... Other AEs: Pancytopenia (1 patient) Sources: Mucositis (severe, 1 patient) Pancreatitis (1 patient) Hyponatremia (1 patient) Hypocalcemia (1 patient) Respiratory distress (1 patient) Melena (1 patient) |
0.15 ug/kg multiple, intravenous (total) Highest studied dose Dose: 0.15 ug/kg Route: intravenous Route: multiple Dose: 0.15 ug/kg Sources: |
unhealthy, 40-77 years n = 2 Health Status: unhealthy Condition: malignant melanoma Age Group: 40-77 years Sex: F Population Size: 2 Sources: |
|
1.5 mg/m2 single, intravenous Highest studied dose Dose: 1.5 mg/m2 Route: intravenous Route: single Dose: 1.5 mg/m2 Sources: |
unknown, children n = 1 Health Status: unknown Age Group: children Population Size: 1 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypocalcemia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Hyponatremia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Melena | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Pancreatitis | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Pancytopenia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Respiratory distress | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
Mucositis | severe, 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months n = 1 Health Status: unhealthy Age Group: 18 months Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. | 1999 Apr |
|
Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis. | 1999 Aug 27 |
|
VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. | 2000 Apr |
|
Testin induction: the role of cyclic 3',5'-adenosine monophosphate/protein kinase A signaling in the regulation of basal and lonidamine-induced testin expression by rat sertoli cells. | 2000 Dec |
|
Carcinogenic nickel induces genes involved with hypoxic stress. | 2000 Jan 1 |
|
Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin--preliminary report about hepatoprotective effect of amifostine. | 2000 May-Jun |
|
Amphetamine induces differential changes in the gene expression of metabotropic glutamate receptor 5 in cultured cortical and hippocampal neurons. | 2001 Aug |
|
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. | 2001 Feb |
|
Cadmium-induced cell transformation and tumorigenesis are associated with transcriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species. | 2001 Jun |
|
Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment. | 2001 Mar |
|
Dual phases of functional change in norepinephrine transporter in cultured bovine adrenal medullary cells by long-term treatment with clozapine. | 2001 May |
|
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. | 2002 Dec 1 |
|
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. | 2002 Jan |
|
Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colony-stimulating factor. | 2002 Jan |
|
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. | 2002 Jan 1 |
|
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. | 2003 Mar 15 |
|
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. | 2003 May 15 |
|
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. | 2003 Oct |
|
Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling. | 2003 Sep 5 |
|
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. | 2004 Dec |
|
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. | 2004 Dec 1 |
|
DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung. | 2004 Feb |
|
Endosulfan-mediated biochemical changes in the freshwater fish Clarias batrachus. | 2004 Mar |
|
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. | 2004 Nov |
|
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats. | 2004 Sep-Oct |
|
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. | 2005 Feb 10 |
|
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors. | 2005 May |
Patents
Sample Use Guides
Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.
Route of Administration:
Intravenous
Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:14:37 GMT 2023
by
admin
on
Sat Dec 16 16:14:37 GMT 2023
|
Record UNII |
1CC1JFE158
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C204
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
NDF-RT |
N0000000233
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
LIVERTOX |
NBK548778
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
IARC | Actinomycin D | ||
|
NDF-RT |
N0000000150
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
NDF-RT |
N0000180850
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
WHO-ATC |
L01DA01
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
||
|
WHO-VATC |
QL01DA01
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1162400
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
3220
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
457193
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
DB00970
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
m4067
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
Dactinomycin
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
SUB129914
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
50-76-0
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
1CC1JFE158
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
C412
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
200-063-6
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
DTXSID9020031
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
1CC1JFE158
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
DACTINOMYCIN
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | Description: An orange-red to red, crystalline powder.Solubility: Soluble in water at 10 ?C and slightly soluble in water at 37 ?C; freely soluble in ethanol (~750 g/l) TS and methanol R;very slightly soluble in ether R.Category: Cytotoxic drug.Storage: Dactinomycin should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 40 ?C.Additional information: Dactinomycin is hygroscopic and is affected by light and heat.CAUTION: Dactinomycin must be handled with care, avoiding contact with the skin and inhalation of airborne particles. | ||
|
SUB13528MIG
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
27666
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
D003609
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1554
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
100000085032
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
1155
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
3100
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
Dactinomycin
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
774
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY | |||
|
3053
Created by
admin on Sat Dec 16 16:14:38 GMT 2023 , Edited by admin on Sat Dec 16 16:14:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||